PubMed · 2023

Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial

Garvey WT, Frias JP, Jastreboff AM, le Roux CW (2023). Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet (London, England).

Lancet (London, England)

View original source

Peptides linked in PeptIQ Wiki

Tirzepatide — community report

This page indexes a published source for discovery and cross-linking. PeptIQ reports what the literature contains and what users track — it does not interpret studies as treatment guidance.